241 related articles for article (PubMed ID: 11706390)
1. Mechanism of action of trastuzumab and scientific update.
Baselga J; Albanell J; Molina MA; Arribas J
Semin Oncol; 2001 Oct; 28(5 Suppl 16):4-11. PubMed ID: 11706390
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells.
Lu Y; Zi X; Pollak M
Int J Cancer; 2004 Jan; 108(3):334-41. PubMed ID: 14648698
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells.
Marches R; Uhr JW
Int J Cancer; 2004 Nov; 112(3):492-501. PubMed ID: 15382077
[TBL] [Abstract][Full Text] [Related]
4. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling.
Lane HA; Motoyama AB; Beuvink I; Hynes NE
Ann Oncol; 2001; 12 Suppl 1():S21-2. PubMed ID: 11521716
[TBL] [Abstract][Full Text] [Related]
5. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways.
Le XF; Pruefer F; Bast RC
Cell Cycle; 2005 Jan; 4(1):87-95. PubMed ID: 15611642
[TBL] [Abstract][Full Text] [Related]
6. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
7. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition.
Le XF; Claret FX; Lammayot A; Tian L; Deshpande D; LaPushin R; Tari AM; Bast RC
J Biol Chem; 2003 Jun; 278(26):23441-50. PubMed ID: 12700233
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J
Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546
[TBL] [Abstract][Full Text] [Related]
9. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.
Le XF; Bedrosian I; Mao W; Murray M; Lu Z; Keyomarsi K; Lee MH; Zhao J; Bast RC
Cell Cycle; 2006 Aug; 5(15):1654-61. PubMed ID: 16861913
[TBL] [Abstract][Full Text] [Related]
10. FOXO1A is a target for HER2-overexpressing breast tumors.
Wu Y; Shang X; Sarkissyan M; Slamon D; Vadgama JV
Cancer Res; 2010 Jul; 70(13):5475-85. PubMed ID: 20551062
[TBL] [Abstract][Full Text] [Related]
11. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.
Nahta R; Takahashi T; Ueno NT; Hung MC; Esteva FJ
Cancer Res; 2004 Jun; 64(11):3981-6. PubMed ID: 15173011
[TBL] [Abstract][Full Text] [Related]
12. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.
Eddy SF; Kane SE; Sonenshein GE
Cancer Res; 2007 Oct; 67(19):9018-23. PubMed ID: 17909003
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
15. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
Yakes FM; Chinratanalab W; Ritter CA; King W; Seelig S; Arteaga CL
Cancer Res; 2002 Jul; 62(14):4132-41. PubMed ID: 12124352
[TBL] [Abstract][Full Text] [Related]
16. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
17. A novel interaction between HER2/neu and cyclin E in breast cancer.
Mittendorf EA; Liu Y; Tucker SL; McKenzie T; Qiao N; Akli S; Biernacka A; Liu Y; Meijer L; Keyomarsi K; Hunt KK
Oncogene; 2010 Jul; 29(27):3896-907. PubMed ID: 20453888
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
Albanell J; Codony J; Rovira A; Mellado B; Gascón P
Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564
[TBL] [Abstract][Full Text] [Related]
19. Anti-epidermal growth factor receptor monoclonal antibody 225 upregulates p27(KIP1) and p15(INK4B) and induces G1 arrest in oral squamous carcinoma cell lines.
Kiyota A; Shintani S; Mihara M; Nakahara Y; Ueyama Y; Matsumura T; Tachikawa T; Wong DT
Oncology; 2002; 63(1):92-8. PubMed ID: 12187077
[TBL] [Abstract][Full Text] [Related]
20. Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect.
Albanell J; Baselga J
J Natl Cancer Inst; 2001 Dec; 93(24):1830-2. PubMed ID: 11752000
[No Abstract] [Full Text] [Related]
[Next] [New Search]
